AI Labs Group S.L.
Bilbao, Basque Country, Spain
NCT Number: NCT07428915
This study aims to determine if an artificial intelligence (AI) medical device can help healthcare professionals more accurately diagnose rare and complex skin conditions. Dermatological issues are common in primary care, but there is often a gap in diagnostic accuracy between general practitioners and specialists, which can lead to treatment delays for serious conditions like Generalized Pustular Psoriasis (GPP) and Hidradenitis Suppurativa (HS).
The researchers hypothesized that the AI device would enhance the diagnostic accuracy of healthcare professionals for GPP and other dermatological conditions. To test this, the study followed a prospective observational design involving 15 practitioners, including both general practitioners and dermatologists.
During the study, participants were asked to evaluate 100 clinical images. For each case, they first provided a diagnosis based on the image and patient history alone. They were then shown the AI's analysis-which included the top five suggested diagnoses and confidence levels-and asked if they would like to adjust their initial assessment.
The primary question the study sought to answer was whether the information provided by the AI device could significantly increase the number of correct diagnoses made by these professionals, particularly for rare diseases that are often difficult to identify in a standard clinical setting
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Bilbao, Basque Country, Spain
This investigation is structured as a multi-reader multi-case (MRMC) study. A cohort of 15 healthcare professionals, including 11 primary care physicians and 4 dermatologists, acted as the "readers". These readers evaluated a "case" set of 100 clinical images to assess diagnostic performance both with and without the assistance of the AI device.
Study Design and Technical Methodology The research was conducted as a prospective observational and cross-sectional study. It utilized a "physician-as-their-own-control" design to measure the impact of Artificial Intelligence (AI) on diagnostic performance.
Quality Assurance and Data Management
To ensure the scientific integrity and reliability of the findings, several quality control measures were implemented:
Statistical Analysis Plan
The primary goal of the analysis was to quantify Top-1 accuracy, sensitivity, and specificity for both general practitioners and dermatologists.
Ethical and Confidentiality Framework The study adhered to UNE-EN ISO 14155:2021, the Declaration of Helsinki, and the General Data Protection Regulation (GDPR).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The intervention consists of a Computer-Aided Diagnosis (CAD) software-only medical device that utilizes computer vision algorithms to analyze digital images of skin structures. During the study, healthcare professionals use the tool as a diagnostic support system to assist in the evaluation of complex dermatological conditions.
Time frame: Day 1
This measure evaluates the Top-1 diagnostic accuracy of healthcare professionals (HCPs) when identifying GPP. Accuracy is calculated by comparing the clinician's diagnosis (both with and without the device's top 5 suggestions) against the confirmed reference diagnosis for each of the clinical cases.
Time frame: Day 1
This measure evaluates the Top-1 diagnostic accuracy of healthcare professionals (HCPs) when identifying the corresponding skin condition. Accuracy is calculated by comparing the clinician's diagnosis (both with and without the device's top 5 suggestions) against the confirmed reference diagnosis for each of the clinical cases.
Time frame: Day 1
This measure evaluates the Top-1 diagnostic accuracy of healthcare professionals (HCPs) when identifying rare dermatological conditions. Accuracy is calculated by comparing the clinician's diagnosis (both with and without the device's top 5 suggestions) against the confirmed reference diagnosis for each of the clinical cases.
AI Labs Group S.L
Industry
A Multi-Reader Multi-Case (MRMC) Study for Assessing the Impact of Legit.Health Plus on the Clinical Assessment of Generalized Pustular Psoriasis and Other Skin Conditions by Healthcare Professionals.
Acronym: LegitHealth BI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04359394
Psoriasis, Pustular Psoriasis (PP)
München, Germany
View Trial DetailsNCT07428954
Acne, Acne Vulgaris
Bilbao, Basque Country, Spain
View Trial DetailsNCT05994976
Acne, Acne Vulgaris
Montreal, Quebec, Canada
View Trial DetailsNCT07549828
Acne, Acne Vulgaris
View Trial Details